Authors:
Sadler, BM
Chittick, GE
Polk, RE
Slain, D
Kerkering, TM
Studenberg, SD
Lou, Y
Moore, KHP
Woolley, JL
Stein, DS
Citation: Bm. Sadler et al., Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J CLIN PHAR, 41(4), 2001, pp. 386-396
Authors:
Polk, RE
Brophy, DF
Israel, DS
Patron, R
Sadler, BM
Chittick, GE
Symonds, WT
Lou, Y
Kristoff, D
Stein, DS
Citation: Re. Polk et al., Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males, ANTIM AG CH, 45(2), 2001, pp. 502-508
Authors:
Brophy, DF
Israel, DS
Pastor, A
Gillotin, C
Chittick, GE
Symonds, WT
Lou, Y
Sadler, BM
Polk, RE
Citation: Df. Brophy et al., Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers, ANTIM AG CH, 44(4), 2000, pp. 978-984
Authors:
Polk, RE
Crouch, MA
Israel, DS
Pastor, A
Sadler, BM
Chittick, GE
Symonds, WT
Gouldin, W
Lou, Y
Citation: Re. Polk et al., Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men, PHARMACOTHE, 19(12), 1999, pp. 1378-1384
Authors:
McDowell, JA
Chittick, GE
Ravitch, JR
Polk, RE
Kerkering, TM
Stein, DS
Citation: Ja. Mcdowell et al., Pharmacokinetics of [C-14]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral doseto HIV-1-infected adults: a mass balance study, ANTIM AG CH, 43(12), 1999, pp. 2855-2861